BAKER BROS. ADVISORS LP recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
Baker Bros. Advisors is a private hedge fund sponsor that is based out of New York City. The company was established in 2000 by Julian Baker and Felix Baker, who continues to have an active role in the company today acting as its co-managing members. Julian Baker has a business background from Harvard and Felix Baker has a PhD in Immunology from Stanford. The company currently has 25 employees with 11 of them being investment advisory professionals or researchers. Baker Bros. Advisors currently falls into the category of catering to less than 10 clients. The firm utilizes a fundamental driven approach to make its investment decisions, emphasizing life sciences companies. The company holds its investments usually for three years, although its more successful investments are held for longer. Baker Bros. Advisors invests almost exclusively in the health care sector, with a much lesser degree of assets allocated in the industrials sector. The firm’s top holdings currently include Pharmacyclics Inc., which alone makes up almost a fifth of its total asset allocations, Incyte Corporation, Synageva Biopharma Corporation, Seattle Genertics Inc., Salix Pharmaceuticals Inc., Acadia Pharmaceuticals Inc., and Biomarin Pharmaceuticals Inc., with its top ten holdings making up more than three quarters of its total holdings. Baker Bros. Baker Bros. Advisors does not believe in diversifying its portfolio, instead focusing on specific companies that it has deemed to be good holdings and placing concentrated positions in their securities that can generate significant returns in the long term. The company has a current market value of over $12 billion, investing almost all of its total available assets. Advisors’s market value has been increasing significantly over time, growing from its $5 billion market valuation just two years prior in 2013 to well over twice that amount today. Baker Bros. Advisors currently provides its products and services to a variety of university foundations, and families.
As of the latest 13F report, the guru’s equity portfolio contained 111 stocks valued at a total of $16.62Bil. The top holdings were SGEN(36.26%), INCY(17.47%), and BGNE(15.44%).
According to GuruFocus data, these were BAKER BROS. ADVISORS LP’s top five trades of the quarter.
Global Blood Therapeutics Inc
The guru sold out of their 3,732,502-share investment in NAS:GBT. Previously, the stock had a 1.67% weight in the equity portfolio. Shares traded for an average price of $68.48999999999999 during the quarter.
On 02/18/2023, Global Blood Therapeutics Inc traded for a price of $68.48999999999999 per share and a market cap of $4.62Bil. The stock has returned 165.36% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Global Blood Therapeutics Inc has a price-book ratio of 38.94, a EV-to-Ebitda ratio of -16.54 and a price-sales ratio of 18.82.
The price-to-GF Value ratio is 0.85, earning the stock a GF Value rank of 6.
ChemoCentryx Inc
The guru sold out of their 1,792,657-share investment in NAS:CCXI. Previously, the stock had a 0.61% weight in the equity portfolio. Shares traded for an average price of $51.92 during the quarter.
On 02/18/2023, ChemoCentryx Inc traded for a price of $51.99 per share and a market cap of $3.74Bil. The stock has returned 49.18% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, ChemoCentryx Inc has a price-book ratio of 15.68, a EV-to-Ebitda ratio of -27.52 and a price-sales ratio of 98.47.
The price-to-GF Value ratio is 1.04, earning the stock a GF Value rank of 5.
Travere Therapeutics Inc
BAKER BROS. ADVISORS LP reduced their investment in NAS:TVTX by 2,074,754 shares. The trade had a 0.33% impact on the equity portfolio. During the quarter, the stock traded for an average price of $21.19.
On 02/18/2023, Travere Therapeutics Inc traded for a price of $17.82 per share and a market cap of $1.14Bil. The stock has returned -36.81% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 2 out of 10.
In terms of valuation, Travere Therapeutics Inc has a price-book ratio of 11.35, a EV-to-Ebitda ratio of -5.46 and a price-sales ratio of 5.13.
The price-to-GF Value ratio is 0.82, earning the stock a GF Value rank of 6.
Forma Therapeutics Holdings Inc
The guru sold out of their 1,886,760-share investment in NAS:FMTX. Previously, the stock had a 0.25% weight in the equity portfolio. Shares traded for an average price of $19.99 during the quarter.
On 02/18/2023, Forma Therapeutics Holdings Inc traded for a price of $20.01 per share and a market cap of $957.69Mil. The stock has returned 13.82% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, Forma Therapeutics Holdings Inc has a price-book ratio of 2.31 and a EV-to-Ebitda ratio of -3.15.
SpringWorks Therapeutics Inc
The guru established a new position worth 1,528,538 shares in NAS:SWTX, giving the stock a 0.24% weight in the equity portfolio. Shares traded for an average price of $24.64 during the quarter.
On 02/18/2023, SpringWorks Therapeutics Inc traded for a price of $30.26 per share and a market cap of $1.89Bil. The stock has returned -45.96% over the past year.
GuruFocus gives the company a financial strength rating of 8 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, SpringWorks Therapeutics Inc has a price-book ratio of 3.08 and a EV-to-Ebitda ratio of -4.66.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
